Drug intelligence / Profile preview

propranolol + oxytocin

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Propranolol + oxytocin is a combination therapy used in obstetrics to augment labor, particularly in cases of dysfunctional or prolonged labor. Propranolol is a beta-adrenergic receptor blocker that increases uterine activity by reversing the suppressive effect of beta-agonists on uterine motility. Oxytocin is a hormone that directly stimulates uterine contractions. When used together, this combination has been shown to shorten the duration of labor (especially the latent phase), reduce the need for cesarean section, and improve outcomes in women with inadequate uterine contractility without significant adverse effects on maternal or neonatal health[1][2][9].

Other names: propranolol and oxytocinoxytocin plus propranolol

Targets

Oxytocin receptorADRB1 (β1)ADRB2 (β2)

Beyond the preview

Go deeper on propranolol + oxytocin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on propranolol + oxytocin.

Explore the full profile